cer efficacy, as evaluated by tumor response rate and time to tumor progression. The problems with the linifanib first-line study, the brivanib first-line study, and the SEARCH study remain unknown. Details are expected to be presented at a forthcoming scientific meeting.
In conclusion, clinical trials of new molecular targeted agents for the treatment of HCC in an adjuvant setting, first-line setting, second-line setting, or in combination with TACE, seem to be experiencing difficulty and yielding poor results. These failures may be attributed to any of the following reasons. First, HCC is usually associated with impaired liver function or liver cirrhosis; therefore, toxicity or intolerability may be enhanced relative to patients with normal liver function, resulting in early discontinuation or dose reduction. Second, aside from resection, there are many effective treatment options for HCC including ablation, TACE [8] , and hepatic arterial infusion chemotherapy [9] . Therefore, post-trial treatment might have affected the results of the primary endpoints such as overall survival.
There is a need for new molecular targeted agents for treating HCC that suppress recurrence after curative treatment or TACE as well as for agents for treating advanced HCC in patients with sorafenib resistance or intolerance. We look forward to positive findings from current or future trials of agents that can overcome the difficulties associated with HCC of the cirrhotic liver.
